Zevra Therapeutics (ZVRA) Liabilities and Shareholders Equity (2014 - 2026)

Zevra Therapeutics has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $278.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 61.3% year-over-year to $278.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 58.67% YoY), and the FY2025 full-year result was $284.7 million, up 59.85% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $278.6 million, down from $284.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $284.7 million in Q4 2025, with the low at $106.6 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $176.9 million across 5 years, with a median of $161.8 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity retreated 14.91% — and 2025, when it soared 77.47%.
• Zevra Therapeutics' Liabilities and Shareholders Equity stood at $115.3 million in 2022, then surged by 49.41% to $172.3 million in 2023, then climbed by 3.37% to $178.1 million in 2024, then jumped by 59.85% to $284.7 million in 2025, then declined by 2.16% to $278.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $278.6 million (Q1 2026), $284.7 million (Q4 2025), and $270.1 million (Q3 2025), per Business Quant data.